Skip to content

Chatbot Implementation In The Clinical Informed Consent Process

Chatbot Implementation In The Clinical Informed Consent Process

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07756515
Enrollment
100
Registered
2026-08-10
Start date
2027-01-01
Completion date
2031-12-17
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Informed Consent

Brief summary

The purpose of this study is to determine the feasibility of implementing the chatbot "CoCo" in the IC process for research studies. We hypothesize that implementing a chatbot into the IC process will facilitate accurate information delivery and enhance participant comprehension and process satisfaction compared to traditional remote consent methods.

Detailed description

Primary Objectives: • To determine the feasibility of implementing a chatbot-facilitated remote informed consent (IC) process. Secondary Objectives * To identify determinants of patient acceptance and usage of the chatbot. * To determine the accuracy and completeness of information delivered via the chatbot. * To determine the quality of the chatbot-facilitated remote IC process. * To determine the feasibility of using the chatbot for patient eligibility verification.

Interventions

OTHERCoCo Chatbot

A patient-facing chatbot designed to obtain informed consent

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ability to understand and willingness to provide informed consent. * Age ≥18 years. * Patients whose preferred language is English. * Patients who are being considered for enrollment in selected clinical research studies. Phase I will be initiated using the Clearinghouse protocol PA11-0852, a non-interventional biomarker study.

Exclusion criteria

N/A

Design outcomes

Primary

MeasureTime frameDescription
Safety and Adverse Events (AEs)Through study completion; an average of 1 yearIncidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Countries

United States

Contacts

CONTACTFunda Meric-Bernstam, MD
fmeric@mdanderson.org(713) 794-1226
PRINCIPAL_INVESTIGATORFunda Meric-Bernstam, MD

UT MD Anderson

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026